1. Home
  2. VVOS vs BLRX Comparison

VVOS vs BLRX Comparison

Compare VVOS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vivos Therapeutics Inc.

VVOS

Vivos Therapeutics Inc.

HOLD

Current Price

$2.05

Market Cap

19.4M

Sector

Health Care

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$3.20

Market Cap

17.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VVOS
BLRX
Founded
2016
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.4M
17.1M
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
VVOS
BLRX
Price
$2.05
$3.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$6.75
$19.00
AVG Volume (30 Days)
116.0K
25.9K
Earning Date
11-19-2025
11-24-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$17,317,000.00
$12,735,000.00
Revenue This Year
$19.45
N/A
Revenue Next Year
$70.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
18.76
N/A
52 Week Low
$1.98
$2.30
52 Week High
$7.95
$14.70

Technical Indicators

Market Signals
Indicator
VVOS
BLRX
Relative Strength Index (RSI) 33.84 44.04
Support Level $2.03 $3.12
Resistance Level $2.33 $3.86
Average True Range (ATR) 0.16 0.25
MACD 0.00 0.02
Stochastic Oscillator 4.35 25.37

Price Performance

Historical Comparison
VVOS
BLRX

About VVOS Vivos Therapeutics Inc.

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: